Aventis Ketek CAP Resistance Claim Needs Larger Trials, Advisory Cmte. Says

Aventis Ketek (telithromycin) needs additional studies in more patients with penicillin- and erythromycin-resistant Streptococcus pneumoniae, FDA's Anti-Infectives Advisory Committee said April 26.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet